Can Seroquel and Strattera Be Prescribed Together?
Yes, quetiapine (Seroquel) and atomoxetine (Strattera) can be prescribed together, but this combination requires careful monitoring due to potential pharmacokinetic interactions and additive cardiovascular effects.
Key Pharmacological Considerations
Metabolic Pathway Interaction
Atomoxetine is primarily metabolized through the CYP2D6 pathway 1, 2. While quetiapine does not directly inhibit CYP2D6 3, the combination has been documented in clinical practice. The FDA label for Strattera specifically notes that drugs inhibiting CYP2D6 can cause substantial increases in atomoxetine plasma exposure, resulting in 10-fold higher AUC and 5-fold higher peak concentrations 2. However, quetiapine is not listed as a CYP2D6 inhibitor.
Cardiovascular Monitoring Requirements
Both medications can independently cause cardiovascular effects that may be additive when combined:
Quetiapine causes orthostatic hypotension and tachycardia, with mean heart rate increases of 7 beats per minute in adults 3. In adolescents, heart rate increases ranged from 3.8 to 13.4 bpm depending on dose 3.
Atomoxetine also affects heart rate and blood pressure, particularly in children and adolescents 1.
Monitor the following at baseline and regularly:
- Heart rate (watch for tachycardia >110 bpm in adolescents, >120 bpm in adults)
- Blood pressure (orthostatic measurements)
- QTc interval on ECG (though quetiapine studies showed no significant QTc prolongation at therapeutic doses 3)
Clinical Evidence
A case report documented acute overdose involving both medications (along with oxcarbazepine), which resulted in prolonged CNS depression and initial QTc prolongation that normalized within 4 days 4. While this was an overdose scenario, it confirms the drugs can interact at the CNS level with additive sedative effects.
Practical Prescribing Algorithm
When combining these medications:
- Start with lower doses of both agents and titrate slowly
- Assess cardiovascular status before initiation (baseline ECG, BP, HR)
- Monitor closely during titration:
- Weekly heart rate and blood pressure checks for first month
- Watch for excessive sedation or CNS depression
- Monitor for orthostatic symptoms (dizziness, syncope)
- Consider CYP2D6 genotype testing if available, as 7% of Caucasians are poor metabolizers who will have significantly higher atomoxetine levels 2
- Educate patients about rising slowly from sitting/lying positions to minimize orthostatic hypotension risk
Common Pitfalls to Avoid
- Don't ignore cardiovascular history: Both drugs carry warnings for preexisting cardiovascular disease 1, 3
- Don't overlook sedation risk: The combination may cause additive CNS depression, particularly during initiation
- Don't forget about alcohol: Quetiapine potentiates cognitive and motor effects of alcohol; counsel patients to limit alcoholic beverages 3
- Don't miss anticholinergic effects: If quetiapine is being used with other anticholinergic medications, this increases risk for severe gastrointestinal hypomotility 3
Special Populations
In children and adolescents, both medications are FDA-approved for ADHD (atomoxetine) 5, 1 and various psychiatric conditions (quetiapine) 3. However, cardiovascular monitoring is even more critical in this population, as heart rate increases with quetiapine were more pronounced (up to 13.4 bpm) 3.
The combination is not contraindicated but requires vigilant clinical oversight, particularly for cardiovascular parameters and CNS effects.